Welcome to our dedicated page for Matinas Biopharm news (Ticker: MTNB), a resource for investors and traders seeking the latest updates and insights on Matinas Biopharm stock.
Matinas BioPharma Holdings, Inc. develops biopharmaceutical therapies using its lipid nanocrystal, or LNC, delivery technology. Company updates center on MAT2203, an oral formulation of amphotericin B for invasive fungal infections, along with broader LNC platform applications for intracellular delivery of small molecules and oligonucleotides.
Recurring MTNB news also covers operating and financial results, clinical and regulatory disclosures, governance changes, shareholder ownership activity, capital-structure matters, and NYSE American continued-listing compliance. The company’s announcements connect its drug-development work with board oversight, financing needs, and public-company requirements.
GH Power announced a definitive Business Combination Agreement with Matinas BioPharma (NYSE American: MTNB) to form GH Power International, a NYSE American‑listed clean energy and critical materials company built around GH Power’s modular reactor technology for hydrogen, power, heat and high‑purity alumina.
Through a court‑approved plan of arrangement in Ontario and a subsequent Delaware merger, GH Power and Matinas will become wholly owned subsidiaries of GH Power International. Existing GH Power equityholders are expected to own about 91% and existing Matinas equityholders about 9% of GH Power International on a fully diluted, treasury‑stock basis, subject to adjustments. Each Matinas common share is expected to convert into 0.1 GH Power International common share.
The combined company’s strategy includes commercializing GH Power’s platform and expanding project development and partnerships in North America and Europe, supported by a targeted $15 million+ PIPE financing that is a condition to closing. Separately, Matinas agreed to sell its lipid nano‑crystal subsidiary and MAT2203 program to Azurity Pharmaceuticals for $4 million upfront cash, up to $17.5 million in milestones, and potential mid‑single‑digit royalties, subject to stockholder approvals and closing of the Business Combination, which is expected in Q4 2026.
Matinas BioPharma (NYSE American: MTNB) agreed to a strategic business combination with GH Power to form GH Power International, a NYSE-listed clean energy and critical materials company focused on modular reactors producing high-purity alumina, clean hydrogen and thermal energy. Existing GH Power holders are expected to own ~91% and Matinas stockholders ~9% of GHP International at closing, with each Matinas common share converting into 0.1 GHP International share, subject to adjustments and conditions.
Matinas also signed a definitive agreement to sell Matinas BioPharma Nanotechnologies, including MAT2203 and the LNC platform, to Azurity Pharmaceuticals for $4.0 million upfront, up to $17.5 million in milestones and future mid-single-digit royalties. Former Series A preferred holders are entitled to 7.5% of all Azurity-related proceeds. Additionally, Matinas closed a $575,000 Series D preferred PIPE and a warrant inducement yielding approximately $2.6 million in gross proceeds, both intended for working capital and general corporate purposes. The GH Power transaction is targeted to close in Q4 2026, subject to shareholder, court, financing and listing approvals.
Matinas BioPharma (NYSE American: MTNB) received a notice on June 24, 2026 that it is not in compliance with NYSE American listing standards requiring minimum stockholders’ equity of $4.0 million and $6.0 million under Sections 1003(a)(ii) and 1003(a)(iii).
The company reported equity of $3.02 million as of March 31, 2026 and $4.83 million as of December 31, 2025, with losses in its five most recent fiscal years. NYSE American accepted Matinas BioPharma’s compliance plan and granted a plan period through October 2, 2027, during which the stock will continue trading, subject to quarterly monitoring and potential delisting if progress is insufficient.
Matinas BioPharma (NYSE: MTNB) received a Notice of Non-Compliance from NYSE American on April 2, 2026 for failing to meet continued listing equity thresholds in Section 1003(a) after reporting losses in the five most recent fiscal years.
As of December 31, 2025 the company reported $4.83 million stockholders' equity, the company has until May 2, 2026 to submit a remedial Plan and may have up to an 18‑month Cure Period if the Plan is accepted. The Notice does not affect current trading and reflects an existing going concern explanatory paragraph.
Matinas BioPharma (NYSE American: MTNB) has announced significant changes to its Board of Directors effective March 11, 2025. The company appointed two biotech industry veterans: Keith Murphy and Edward Neugeboren as independent board members, while Matthew Wikler, M.D., and Natasha Giordano stepped down.
Murphy, currently Director and Executive Chairman of Organovo Holdings and CEO of Viscient Bio, will chair the Nominating and Governance Committee and join the Compensation Committee. His background includes founding Organovo and spending ten years at Amgen, where he led global operations for denosumab.
Neugeboren, with over 33 years of healthcare experience, will become Chair of the Compensation Committee and join the Audit Committee. He currently serves on Grace Therapeutics' Board and is Chief Strategy Officer at Cronus Pharma, bringing extensive experience in pharmaceutical operations, business development, and corporate management.
Matinas BioPharma (NYSE American: MTNB) has entered into a securities purchase agreement with investors for the sale of 3,300 shares of Series C Convertible Preferred Stock and warrants for $3.3 million in gross proceeds. The transaction includes two closings of $1.65 million each, with the second closing subject to shareholder approval.
The Preferred Stock will be convertible into common stock at $0.586 per share, with each preferred share initially convertible into 1,706 common shares. The warrants have a $0.6446 exercise price and a five-year term. The funds will be used for general corporate purposes, focusing on reducing operating expenses and exploring strategic alternatives for MAT2203, their Phase 3-ready antifungal drug candidate.
Additionally, Dr. Robin L. Smith has been appointed to the Board of Directors, bringing extensive experience in the biopharmaceutical industry, while founding Chairman Herbert J. Conrad has resigned and will retire.
Matinas BioPharma Holdings (NYSE American: MTNB) has announced the appointment of Evelyn D'An to its Board of Directors as an independent director and Chair of the Audit Committee, effective February 5, 2025. D'An brings significant experience as a board director and financial leader, with extensive expertise in corporate governance, financial oversight, and accounting across both public and private companies. She is a former partner at Ernst & Young, where she spent 18 years serving clients in retail, consumer products, and technology sectors. In addition to chairing the Audit Committee, D'An will serve as a member of the Matinas Nominating & Governance Committee.
111 Equity Group and its principal have acquired a 5.17% ownership stake in Matinas Biopharma Holdings (NYSE American: MTNB) as of January 2, 2025, with additional shares purchased thereafter. The investment follows MTNB's October 2024 announcement of a strategic review. 111 Equity identifies several potential value enhancement opportunities, including:
- Monetizing assets like MAT2203 (Phase 3 ready antifungal drug candidate)
- Leveraging MTNB's NYSE listing for potential mergers
- Utilizing MTNB's balance sheet
As of November 13, 2024, MTNB reported $10,295,000 in cash (approximately $2.13 per share), significantly above its January 16, 2025 closing price of $0.55. Despite an 80% workforce reduction and subsequent cash burn, 111 Equity believes the remaining cash exceeds MTNB's current market cap. The firm is actively engaging with MTNB management to enhance shareholder value.
Matinas BioPharma (NYSE American: MTNB) has received a noncompliance notice from NYSE American on January 6, 2025. The notice was issued because the company failed to hold its annual stockholders meeting for the fiscal year ending December 31, 2024, violating Section 704 of the NYSE American Company Guide.
To address this compliance issue, the company has stated its intention to hold the annual meeting by December 31, 2025, which would bring it back into compliance with NYSE American listing standards.
Matinas BioPharma (NYSE American: MTNB) announces the termination of negotiations for global rights to MAT2203, its oral formulation of amphotericin B. In response, the company has implemented an immediate 80% workforce reduction, eliminating 15 positions including three senior management members. The company has ceased all product development activities to conserve cash. The Board plans to retain an advisor to explore potential sale of MAT2203, their Phase 3-ready antifungal drug candidate, and will evaluate other alternatives including possible company winddown and dissolution.